Benefit Plan Design and Prescription Drug Utilization Among Asthmatics: Do Patient Copayments Matter?

Crown William H., Berndt Ernst R., Onur Baser, Finkelstein Stan N., Witt Whitney P., Maguire Jonathan and Haver Kenan E.
Additional contact information
Crown William H.: Medstat
Berndt Ernst R.: MIT Sloan School and NBER
Finkelstein Stan N.: MIT Sloan School
Witt Whitney P.: Northwestern University
Maguire Jonathan: Medstat
Haver Kenan E.: Massachusetts General Hospital

Forum for Health Economics & Policy, 2004, vol. 7, issue 1, 35

Abstract: The ratio of controller-to-reliever medication use has been proposed as a measure of treatment quality for asthma patients. In this study we examine the effects of plan-level mean out-of-pocket asthma medication patient copayments and other features of benefit plan design on the use of controller medications alone, controller and reliever medications (combination therapy), and reliever medications alone. The 1995-2000 MarketScanTM claims data were used to construct plan-level out-of-pocket copayment and physician/practice prescriber preference variables for asthma medications. Separate multinomial logit models were estimated for patients in fee-for-service (FFS) and non-FFS plans relating benefit plan design features, physician/practice prescribing preferences, patient demographics, patient comorbidities, and county-level income variables to patient-level asthma treatment patterns. We find that the controller-to-reliever ratio rose steadily over 1995-2000, along with out-of-pocket payments for asthma medications, which rose more for controllers than for relievers. After controlling for other variables, however, plan-level mean out-of-pocket copayments were not found to have a statistically significant influence on patient-level asthma treatment patterns. On the other hand, physician/practice prescribing patterns strongly influenced patient-level treatment patterns. There is no strong statistical evidence that higher levels of out-of-pocket copayments for prescription drugs influence asthma treatment patterns. However, physician/practice prescribing preferences influence patient treatment.

Date: 2004
References: View complete reference list from CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
https://doi.org/10.2202/1558-9544.1053 (text/html)
For access to full text, subscription to the journal or payment for the individual article is required.

Related works:
Chapter: Benefit Plan Design and Prescription Drug Utilization Among Asthmatics: Do Patient Copayments Matter? (2004)
Working Paper: Benefit Plan Design and Prescription Drug Utilization Among Asthmatics: Do Patient Copayments Matter? (2003)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bpj:fhecpo:v:7:y:2004:n:5

Ordering information: This journal article can be ordered from
https://www.degruyter.com/journal/key/fhep/html

DOI: 10.2202/1558-9544.1053

Access Statistics for this article

Forum for Health Economics & Policy is currently edited by Dana Goldman

More articles in Forum for Health Economics & Policy from De Gruyter
Bibliographic data for series maintained by Peter Golla ().